Introduction
Medicine information centres (MICs) support pharmacovigilance activities by providing information that aids in assessing, managing and reporting adverse drug reactions (ADRs) [1, 2] . ADRs account for a large proportion of MIC queries, ranging from 14 to 42 % [3] [4] [5] [6] . The MIC at the University of Cape Town, South Africa, an independent drug information centre, was established in 1980. In 2008, a national HIV health care worker (HCW) hotline was established within the MIC to support the public sector antiretroviral roll out in South Africa. The hotline service was expanded to include tuberculosis in 2012. The National HIV & Tuberculosis HCW Hotline supports the clinical management of people living with HIV and/or tuberculosis by answering telephonic queries about HIV and tuberculosis-related topics, including diagnosis, clinical management, laboratory and clinical monitoring, postexposure prophylaxis and adverse drug reactions. Queries come from a range of HCWs, predominantly doctors, nurses and pharmacists. Queries are handled by the MIC team of drug information pharmacists, supported by an established network of experienced clinicians. The details of the hotline have been described previously [7] .
Previous descriptions of HIV hotline services do not provide details of reported ADRs, causality, severity, preventability, implicated drugs or patient outcomes [7] [8] [9] [10] [11] . In addition, literature from resource-limited settings has been restricted to general descriptions of queries received by MICs [6, 12, 13] . Analysis of ADR queries received by the HIV & Tuberculosis HCW Hotline could identify common ADRs, which can be used to select priority topics for HCW training, to inform treatment guidelines and improve patient safety and clinical outcomes.
We analysed ADR queries received by the HIV & Tuberculosis HCW Hotline. Our objectives were (1) to describe the pattern, causality, severity and preventability of ADRs; (2) to identify commonly implicated drugs; (3) to determine HCW concordance with advice given; and (4) to report on patient outcomes.
Methods

Setting
In this study, we analysed ADR queries received by the National HIV & Tuberculosis HCW Hotline at the MIC, located in the Division of Clinical Pharmacology, University of Cape Town, South Africa. The MIC receives calls from both the private and the public healthcare sector.
Study Design and Population
We included all queries received by the HIV & Tuberculosis HCW Hotline about suspected ADRs in HIV-infected patients, and/or patients taking antiretrovirals and/or antituberculosis therapy during the first 18 months (1 May 2013 to 31 October 2014) of implementing an enhanced HIV and tuberculosis ADR surveillance system within the hotline. HIV and tuberculosis queries were received by a team of drug information pharmacists supported by a team of clinicians with expertise in HIV and tuberculosis management. A dedicated information pharmacist contacted reporting HCWs telephonically for follow-up information on the ADRs. Data required for preventability assessment was included in ADR follow up from 1 June 2014.
Data Collection
We prospectively collected patient demographics, drug history, details of the suspected ADR and advice provided by the HIV & Tuberculosis HCW Hotline at the time of the initial query. We collected data regarding the HCW's actions and the patient's outcome during a follow-up call, approximately 1 month after the initial query. Both baseline and follow-up data were collected using standardized data collection forms (see Electronic Supplementary Material 1). A database of all HIV and tuberculosis-specific queries is maintained.
We performed causality assessment using World Health Organization Uppsala Monitoring Centre (WHO-UMC) causality criteria [14] , and included ADRs classified as certain, probable or possible in our analysis. ADR severity was determined using the Division of AIDS (DAIDS) classification system [15] . We categorized ADR severity into one of two categories: mild/moderate if the ADR was graded 1 or 2 or severe if the ADR was graded 3 or 4. We used a dual severity categorization to reflect drug discontinuations: grades 1 and 2 generally do not require drug discontinuations, whilst grades 3 and 4 required drug discontinuations in most cases. We assessed preventability using a modified version of the Schumock and Thornton criteria [16] in a subset of queries from 1 June 2014 onwards, when preventability assessment questions were incorporated in the standardized data capture forms. The modification was to split the first Schumock and Thornton question into two, to distinguish between inappropriate initiation and inappropriate continuation of a drug. Preventability categories used were as follows: drug inappropriately initiated, drug inappropriately continued, history of allergy to drug, inappropriate dose/route of administration, laboratory monitoring not performed, compliance contributed to ADR, drug interaction involved, serum concentration above therapeutic range. We categorized the ADR as preventable if one or more of these categories was fulfilled. Causality, severity, and preventability assessments were performed by a pharmacist, who discussed reports with a clinical pharmacologist and/ or a physician where necessary. When reports were assessed by more than one person, decisions were made by consensus.
Ethical Approval
The study was approved by the Faculty of Health Sciences Human Research Ethics Committee, University of Cape Town (UCT). The UCT Human Research Ethics Committee has Federal Wide Assurance (FWA) for the Protection of Human Subjects accreditation with the US Department of Health and Human Services.
Data Analysis
We used STATA version 13 for data analysis. We calculated frequencies and proportions to describe categorical data.
Results
We received 772 patient-specific queries concerning suspected ADRs involving 734 patients. This comprised 8. Using the WHO-UMC causality assessment categories, we classified the 772 suspected ADRs as shown in Fig. 1 . We included the 624 ADRs categorized as certain, probable or possible, in 601 patients, in further analysis. 578/601 patients (96 %) had a single ADR reported, while 23/601 patients (3.8 %) each had two ADRs reported. There were a total of 950 drug suspects for the 624 ADRs categorized as certain, probable or possible: 440 (70.5 %) ADRs had one drug suspect, 143 (22.9 %) ADRs had two to three drug suspects and 41 (6.6 %) ADRs had four or more drug suspects.
Patient Characteristics
The characteristics of the 601 patients with 624 ADRs are described in Table 1 .
In patients taking antiretroviral therapy (ART) for treatment of HIV infection (n = 549), nucleoside reverse transcriptase inhibitors (NRTIs) were combined with efavirenz in 411 (74.9 %), nevirapine in 24 (4.4 %) and ritonavir-boosted regimens in 113 (20.6 %).
The NRTI backbone was tenofovir and emtricitabine/lamivudine in 384 (69.9 %), zidovudine and lamivudine in 73 (13.3 %), stavudine and lamivudine in 42 (7.7 %) and abacavir and lamivudine in 38 (6.9 %). Less common ART backbones were zidovudine and didanosine (three patients), abacavir and zidovudine (one patient) and a triple-ART backbone consisting of zidovudine, tenofovir, and lamivudine (one patient).
Adverse Drug Reactions (ADRs)
and Corresponding Drug Suspects
The four most common ADRs were rash in 110/624 (17.6 %), drug-induced liver injury (DILI) in 87/624 (13.9 %), kidney injury in 77/624 (12.3 %) and gynaecomastia in 66 (10.6 %) ( Table 2 ). The severity grading of the three most common ADRs and implicated drugs are listed in Table 3 . Efavirenz was implicated in 74/110 (67.3 %) reports of rashes, either alone or in combination with other potentially causative drugs: co-trimoxazole in 21 reports, antituberculosis treatment (rifampicin, isoniazid, pyrazinamide or ethambutol) in 14 reports, tenofovir and/or emtricitabine in four reports, abacavir in three reports, and captopril/furosemide in one report each.
Efavirenz and anti-tuberculosis drugs (rifampicin, isoniazid or pyrazinamide) were the most commonly implicated drugs in DILI reports. Efavirenz was implicated in 37/87 (42.5 %) reports of DILI, either alone or in combination with other drugs: anti-tuberculosis treatment (rifampicin, isoniazid or pyrazinamide) in six reports, cotrimoxazole in nine reports, lopinavir/ritonavir in one report, simvastatin in one report and fluconazole in one report.
Tenofovir was implicated in 72/77 (93.5 %) reports of kidney injury, either alone or in combination with other drugs: rifampicin in two reports, amphotericin B, kanamycin, streptomycin and hydrochlorothiazide (in one report each).
Efavirenz was implicated in all 66 reports of gynaecomastia, either alone or in combination with isoniazid in 14 reports.
Mitochondrial toxicities (hyperlactataemia, lactic acidosis, lipoatrophy, and peripheral neuropathy) occurred less frequently, accounting for 36 (5.8 %) of the total ADRs. Stavudine was implicated in 16/36 (44.4 %) reports (Table 2 ).
Common Drug Suspects with Corresponding
ADRs and Severity Assessment
Overall, efavirenz was the most commonly implicated drug suspect, implicated in 42.9 % (268/624) of ADRs reported (Table 4 ). In particular, efavirenz was associated with all reports of gynaecomastia (n = 66), 94.7 % (18/19) of reports of psychosis, 67.3 % (74/110) of reports of rash and 72.9 % (43/59) of reports of neurological ADRs.
Preventability of ADRs
This analysis is restricted to a sub-group of ADRs reported between 1 June 2014 (when preventability questions were incorporated into the standardized data collection forms) and 31 October 2014. We included a total of 223 ADRs in 211 patients. Forty (17.9 %) of the ADRs were preventable, and 183 (82.1 %) ADRs were not preventable. The top three preventable ADRs were DILI, kidney injury and rash, comprising 11 (27.5 %), 8 (20.0 %) and 3 (7.5 %) of the 40 preventable ADRs, respectively. Of the 11 DILI reports considered to be preventable, nine reports were also classified as severe/ life threatening. The most frequent reasons for preventability were continuation of drug therapy despite clinical features or laboratory markers of toxicity where drug therapy should have been stopped, inappropriate drug therapy and previous history of allergy or drug reaction ( Table 5 ). The drug suspects associated with these preventability criteria are listed in Table 5 .
National HIV & Tuberculosis HCW Hotline Recommendations and HCW Actions Taken
There were 596 hotline recommendations and HCW actions taken corresponding to 596 drug suspects. Drug substitution or continuation of the suspected drug, with supportive care, were the most common recommendations and actions taken (Table 6 ).
HCW Concordance with Advice and Patient Outcomes
We obtained follow-up information for 383 (63.7 %) patients. Of these, 275 (71.8 %) were managed as outpatients and 83 (21.7 %) as inpatients. Level of management was not recorded in 25 (6.5 %). Reasons for the MIC's inability to get follow-up information, where documented, included queries for which HCWs did not consent to be contacted for follow-up (n = 28), where HCWs moved to other facilities (n = 6), HCWs could not remember the patient about whom they had called (n = 3), or where the patient had been lost to follow-up (n = 3). In most cases, HCWs could simply not be reached for telephonic followup despite all our attempts (n = 78). HCWs followed all advice given in 314/399 (78.7 %) ADRs, followed some advice in 58/399 (14.5 %) ADRs, and did not follow any advice in 24/399 (6.0 %) ADRs. Concordance could not be determined in three (0.8 %) ADRs, as in these cases, management of the ADR was unknown. At follow-up, patient outcomes for the ADR were mostly favourable, with 254 (66.3 %) patients recording improvement, nine (2.3 %) patients with complete resolution, six (1.6 %) patients with deterioration, 32 (8.4 %) were unchanged, 10 (2.6 %) died and 72 (18.8 %) patients had unknown status at follow-up.
Deaths
Ten patients with suspected ADRs died during the study period (drug suspects listed in brackets): five with acute kidney injury (tenofovir and rifampicin), three with DILI (efavirenz, co-trimoxazole and rifampicin) one with both DILI and acute kidney injury (tenofovir and rifampicin) and one with thrombocytopaenia (rifampicin). In three patients, the ADR was assessed as having contributed directly to the death: cholestatic DILI due to either rifampicin or co-trimoxazole, kidney injury due to tenofovir, and DILI with acute kidney injury due to rifampicin and/or tenofovir. In the patient with cholestatic DILI due to either rifampicin or co-trimoxazole, the hotline recommended rechallenge with rifampicin once the cholestasis had resolved. In this patient, liver injury recurred after rechallenge.
Discussion
Over an 18-month period, the MIC responded to 624 ADRrelated queries from healthcare workers contacting the HIV/tuberculosis hotline. About one in six ADRs were considered preventable. The most common ADRs about which healthcare workers requested advice were rashes, DILI, and kidney injury, which correspond to the known ADR profiles of antiretrovirals and antituberculosis drugs used in standardized regimens in South Africa. About nine out of every ten reports of DILI, about one in three reports ADRs adverse drug reaction, ART antiretroviral therapy, PEP post-exposure prophylaxis, PMTCT prevention of mother-to-child transmission of kidney injuries, and about one in four reports of rash were rated as severe. Three patients had died with an ADR considered to have contributed directly to the death. To our knowledge, this is the first study from a resourcelimited setting that describes the pattern, severity, preventability, causality and outcomes of ADRs reported to an MIC in patients with HIV and/or tuberculosis. Patients being treated for HIV and/or tuberculosis usually take multiple drugs, with shared and sometimes additive or synergistic side effects. Causality assessment of ADRs with multiple drug suspects and overlap in presentation with underlying disease is challenging. Decisions regarding management of ADRs due to antiretrovirals and tuberculosis treatment are also challenging. Therapeutic options are often limited, and there is frequently an urgent need to treat the underlying disease. This results in consideration of rechallenge even when causality is likely. For example, in cases of DILI due to first-line antituberculosis treatment, patients frequently require rechallenge with rifampicin and isoniazid because of limited treatment options and inferior tuberculosis outcomes if rifampicin and isoniazid are not included in the treatment regimen [17, 18] . These ABC abacavir, ADR adverse drug reaction, ATV/r atazanavir/ritonavir, AZT zidovudine, D4T stavudine, DDI didanosine, EFV efavirenz, FTC emtricitabine, GIT gastrointestinal tract, HCTZ hydrochlorothiazide, LPV/r lopinavir/ritonavir, NVP nevirapine, TDF tenofovir, 3TC lamivudine a More than one drug suspect may be implicated for each ADR b Dermatology (other) includes one report each of skin warts, scleroderma and erythema nodosum c GIT intolerance includes nausea, vomiting, diarrhoea d Other includes one report each of fever, vaginal pain and weight loss challenges may be reflected by HCWs' use of the telephonic hotline service for assistance. The majority of ADR queries came from doctors. This finding is similar to another HIV hotline service from a resource-limited setting [10] . The proportion of ADR queries coming from nurses (25.7 %) was approximately double that seen in an analysis of queries to our hotline service in 2011 [7] , which may reflect both the scale-up of nurse initiation of ART in South Africa and the increasing awareness of our service among nurses. There are ongoing efforts to increase awareness of the hotline service, including monthly HCW newsletters and distribution of educational material about important HIV and TB-related topics.
Queries regarding rashes, DILI and kidney injury were the most frequent. Efavirenz was the most commonly implicated drug associated with rashes, efavirenz together with first-line anti-tuberculosis drugs (rifampicin, isoniazid or pyrazinamide) were the most frequent causes of DILI, and tenofovir was the most frequent cause of kidney injury. These findings reflect the known ADR profiles of antiretrovirals used in standardized regimens in the public sector treatment programme in South Africa [19] and the high burden of tuberculosis in this setting [20] . Conversely, queries regarding mitochondrial toxicities such as peripheral neuropathy, lipoatrophy, hyperlactataemia and lactic acidosis were infrequent, and most cases were caused by stavudine. Stavudine has largely been replaced by tenofovir following new recommendations in the 2010 South African adult ART guidelines, because of its toxicity [19] .
The ADR was severe in the majority (88.5 %) of reports of DILI. Anti-tuberculosis treatment was implicated in 39.1 % of DILI reports, often in combination with other drugs. DILI due to anti-tuberculosis treatment was recently identified as the second most common cause of ADR-related deaths in medical wards in South Africa [21] . The frequency of queries regarding severe DILI highlights the need for training of HCWs in diagnosis and management of this ADR.
In the sub-group analysis, we found that continuation of drug therapy despite symptoms or laboratory markers of toxicity was the most frequent preventability criterion reported. This finding may be a reflection of lack of knowledge on the prompt recognition and appropriate management of ADRs, a result of overburdened HCWs failing to respond to laboratory results in a timely manner, or system failures resulting in HCWs not receiving results from the laboratory timeously. Each of these possibilities warrants further investigation in our setting.
HCW concordance with advice was high. This finding is comparable with studies from high-income countries, although these studies included ADR queries in addition to other types of queries (e.g. rational drug selection queries, Table 3 ADR severity of the three commonest ADRs using DAIDS severity criteria and corresponding drug suspects questions about indications and contraindications, the administration or dose, drug interactions, queries about the availability or supply of drugs, drug identification queries, and non-clinical queries, such as drug costs or legal issues [4, 22, 23] ). Our study has limitations. First, it is an analysis of telephonic ADR queries with no denominator, and does not reflect ADR prevalence in South Africa. However, it gives insight into the ADRs that HCWs encounter that require assistance and additional information with respect to diagnosis and/or management. Second, we determined patient outcomes based on telephonic follow-up with HCWs and had no access to patient records to confirm outcomes. Third, drug exposure histories may not be complete, as they rely on information available to the HCW making the query. In particular, exposure to over-the-counter drugs and complementary and traditional remedies may not be completely captured and/or recorded. Fourth, we did not obtain complete follow-up data on all patients, which may have introduced bias in our observed follow-up analysis, as HCWs who could be contacted may have been more likely to adhere to our recommendations. Finally, we were only able to assess ADR severity and preventability in a sub-set of reports due to insufficient data, and we did not validate our modification of the preventability assessment tool.
Conclusion
Rashes, DILI and kidney injury were the most frequent ADRs about which HCWs sought advice from the National HIV & Tuberculosis HCW Hotline. Guidance on diagnosis and management of these ADRs should be prioritized for inclusion in HCW training. In cases with follow-up History of allergy or previous reaction to the drug 7 EFV (4), co-trimoxazole (1), LPV/r (1), AZT (1) Dose/route of administration not appropriate for patient 3 LPV/r (2), EFV (1) Laboratory monitoring not performed 3 TDF (2), AZT (1) Compliance contributed to the reaction 3 EFV (3)
Drug interaction involved 1 Amiodarone (1)-interaction with LPV/r Serum concentration above the therapeutic range 0 N/A ADR adverse drug reaction, ATV/r atazanavir/ritonavir, AZT zidovudine, EFV efavirenz, LPV/r lopinavir/ritonavir, TDF tenofovir a More than one preventability criteria may be applicable to each preventable ADR information, concordance with advice was good and HCWs reported improvement in the majority of patients. As the HIV treatment programme expands in South Africa, it will be essential to enhance the national hotline's outreach and strengthen its utility both for ADR surveillance and clinical decision support for HCWs. Furthermore, further studies are needed to assess the preventability of ADRs in a larger sample of patients.
